Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

IDEXX Laboratories Inc Stock Research

IDXX

437.24USD+1.55(+0.36%)Market Closed
Watchlist

Market Summary

USD437.24+1.55
Market Closed
0.36%

IDXX Alerts

  • 2 major insider sales recently.
  • Big jump in Earnings (Y/Y)

IDXX Stock Price

IDXX RSI Chart

IDXX Valuation

Market Cap

36.3B

Price/Earnings (Trailing)

45.89

Price/Sales (Trailing)

10.33

EV/EBITDA

31.12

Price/Free Cashflow

61.27

IDXX Price/Sales (Trailing)

IDXX Profitability

Operating Margin

59.71%

EBT Margin

25.83%

Return on Equity

83.13%

Return on Assets

24.9%

Free Cashflow Yield

1.63%

IDXX Fundamentals

IDXX Revenue

Revenue (TTM)

3.5B

Revenue Y/Y

9.65%

Revenue Q/Q

4.83%

IDXX Earnings

Earnings (TTM)

791.4M

Earnings Y/Y

69.9%

Earnings Q/Q

4.76%

Price Action

52 Week Range

317.06564.74
(Low)(High)

Last 7 days

-3.3%

Last 30 days

-13.4%

Last 90 days

-10.7%

Trailing 12 Months

33.6%

IDXX Financial Health

Current Ratio

1.08

IDXX Investor Care

Buy Backs (1Y)

1.03%

Diluted EPS (TTM)

9.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for IDXX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-06
AYERS JONATHAN W
gifted
-
-
-147,821
-
2023-09-06
AYERS JONATHAN W
gifted
-
-
147,821
-
2023-09-01
Smith Martin Alexander
acquired
-
-
19.00
executive vice president
2023-09-01
AYERS JONATHAN W
gifted
-
-
-250
-
2023-09-01
Smith Martin Alexander
sold (taxes)
-2,556
511
-5.00
executive vice president
2023-08-31
MAZELSKY JONATHAN JAY
acquired
1,067,740
79.54
13,424
president and ceo
2023-08-31
AYERS JONATHAN W
gifted
-
-
-1,250
-
2023-08-31
MAZELSKY JONATHAN JAY
sold
-6,873,270
512
-13,424
president and ceo
2023-08-29
POLEWACZYK JAMES F
acquired
2,438,480
144
16,909
executive vice president
2023-08-29
POLEWACZYK JAMES F
sold
-11,696,400
510
-22,909
executive vice president

1–10 of 50

Which funds bought or sold IDXX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
added
23.2
29,667
154,687
0.01%
2023-09-21
Jefferies Group LLC
new
-
2,117,700
2,117,700
0.02%
2023-09-20
BARCLAYS PLC
added
95.78
41,798,000
85,064,000
0.05%
2023-09-14
IMS Capital Management
reduced
-3.04
-10,789
400,277
0.22%
2023-09-12
Farther Finance Advisors, LLC
added
4.17
1,108
25,112
-%
2023-09-07
ACADEMY CAPITAL MANAGEMENT INC/TX
reduced
-0.73
-53,519
17,562,500
3.52%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
added
3.43
131,637
3,531,680
0.41%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
2.00
503
-%
2023-08-30
Western Wealth Management, LLC
unchanged
-
4,684
1,094,360
0.09%
2023-08-29
Garde Capital, Inc.
unchanged
-
1,000
309,000
0.03%

1–10 of 47

Latest Funds Activity

Are funds buying IDXX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own IDXX
No. of Funds

Schedule 13G FIlings of IDEXX Laboratories

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
fundsmith llp
5.37%
4,447,828
SC 13G
Feb 14, 2023
fundsmith llp
5.37%
4,447,828
SC 13G
Feb 09, 2023
vanguard group inc
9.82%
8,132,479
SC 13G/A
Jan 26, 2023
blackrock inc.
10.3%
8,502,881
SC 13G/A
Jan 20, 2023
blackrock inc.
10.3%
8,502,881
SC 13G/A
Feb 10, 2022
vanguard group inc
9.34%
7,923,466
SC 13G/A
Jan 27, 2022
blackrock inc.
10.6%
8,990,586
SC 13G/A
Jan 25, 2022
blackrock inc.
10.6%
8,990,586
SC 13G/A
Sep 09, 2021
blackrock inc.
10.1%
8,612,405
SC 13G/A
Feb 12, 2021
fundsmith llp
4.95%
4,226,428
SC 13G/A

Recent SEC filings of IDEXX Laboratories

View All Filings
Date Filed Form Type Document
Sep 08, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 06, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading
Sep 05, 2023
4
Insider Trading
Aug 31, 2023
144
Notice of Insider Sale Intent
Aug 31, 2023
4
Insider Trading
Aug 29, 2023
144
Notice of Insider Sale Intent
Aug 17, 2023
4
Insider Trading
Aug 14, 2023
4
Insider Trading

Peers (Alternatives to IDEXX Laboratories)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.1B
30.4B
-2.55% -6.78%
29.25
6.13
-1.49% 0.14%
169.6B
40.2B
-6.64% -2.43%
32.87
4.22
-11.68% -39.67%
106.4B
31.6B
-4.08% -3.94%
29.34
3.37
1.57% -30.40%
36.3B
3.5B
-13.39% 33.61%
45.89
10.33
6.21% 19.20%
27.8B
2.9B
-5.23% 47.17%
53.51
9.68
-2.14% -24.34%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.17
10.1
16.30% 250.21%
4.5B
1.1B
-6.83% -12.71%
135.07
4.01
69.36% 3.03%
4.2B
822.4M
-17.77% 27.32%
-184
5.12
56.01% -147.34%
-
-
-12.36% -2.62%
-
-
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.2B
254.9M
2.45% 31.18%
-62.25
4.89
-1.22% 15.74%
664.8M
240.7M
-6.95% -50.26%
-15.57
2.76
4.82% 85.44%
43.3M
9.0M
56.07% -12.11%
-2.4
4.79
20.81% 50.13%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

IDEXX Laboratories News

Defense World
Head-To-Head Review: Medical Imaging (OTCMKTS:MEDD ....
Defense World,
19 hours ago
Insider Monkey
5 Best Mid-Cap Growth ETFs.
Insider Monkey,
2 days ago
London South East
Investing.com UK

Returns for IDXX

Cumulative Returns on IDXX

24.4%


10-Year Cumulative Returns

21.5%


7-Year Cumulative Returns

12.6%


5-Year Cumulative Returns

5.8%


3-Year Cumulative Returns

Risks for IDXX

What is the probability of a big loss on IDXX?

68.8%


Probability that IDEXX Laboratories stock will be more than 20% underwater in next one year

38.5%


Probability that IDEXX Laboratories stock will be more than 30% underwater in next one year.

18.5%


Probability that IDEXX Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does IDXX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if IDEXX Laboratories was unfortunately bought at previous high price.

Drawdowns

Financials for IDEXX Laboratories

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.4%3,5143,4313,3673,3403,3093,2743,2153,1353,0472,8582,7072,5912,4752,4572,4072,3512,2912,2522,2132,1702,117
Cost Of Revenue1.8%1,4071,3821,3631,3641,3661,3571,3261,3081,2881,2281,136---1,041---972956934
Gross Profit2.9%2,1072,0492,0041,9761,9421,9171,8891,8431,7921,6821,5711,4931,4151,3941,3661,3351,2951,2701,2421,2141,182
  S&GA Expenses1.9%550540525521515504487474458433434424421428418408399394387382376
  R&D Expenses-29.6%183259255257249164161154152146141138134135133128123120118117115
EBITDA-100.0%-1,0461,0129839621,0391,0371,020964896791720685654641------
EBITDA Margin-100.0%-0.30*0.30*0.29*0.29*0.32*0.32*0.33*0.32*0.31*0.29*0.28*0.28*0.27*0.27*------
Interest Expenses4.8%48.0046.0040.0034.0030.0029.0030.0030.0031.0033.0033.0033.0032.0030.0031.0032.0034.0034.0035.0036.0037.00
Earnings Before Taxes13.0%1,001886860839823904903888833765662593562534522521497478458440423
EBT Margin-100.0%-0.26*0.26*0.25*0.25*0.28*0.28*0.28*0.27*0.27*0.24*0.23*0.23*0.22*0.22*------
Net Income13.2%791699679670664735745757728674582498460437428423407390377330307
Net Income Margin-100.0%-0.20*0.20*0.20*0.20*0.22*0.23*0.24*0.24*0.24*0.21*0.19*0.19*0.18*0.18*------
Free Cashflow-100.0%-456394448439615636663694666541446367287304------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets2.2%2,8712,8082,7472,6402,6072,5932,4372,3862,4122,3272,2952,0471,9611,8861,8321,7511,7241,6811,5371,5451,521
  Current Assets2.6%1,1791,1491,1011,0591,0431,0909569381,0011,0981,063869780721680703712698654704740
    Cash Equivalents19.3%13311111399.0011420514414523235138417610581.0090.00104111117124147175
  Inventory1.1%395391368355333302269258241226210218229212195205197189173180176
  Net PPE2.7%683665649612594593588573550544555548551546534497470449437410394
  Goodwill0.3%3643633623553563613594.0010924324323823523.0024025.0021521521420.00196
Liabilities-9.7%1,7771,9672,1382,1642,1501,9531,7471,6301,6641,6241,6621,6061,6871,7781,6551,5491,5531,6291,6291,5461,562
  Current Liabilities-17.1%8841,0661,2361,1901,167971764634652621583527541846725627619690770760774
    LT Debt, Current0.0%75.0075.0075.00---75.0075.0012512550.0050.00---------
    LT Debt, Non Current0.1%697696694761768773775778780779858853--699------
Shareholder's Equity30.1%1,09484160947645764069075574870363344127310817820317252.00---
  Retained Earnings5.9%4,0383,8143,6003,4273,2463,1142,9202,7582,5822,3802,1762,0011,8551,7061,5961,5051,3961,2711,1681,082989
  Additional Paid-In Capital1.7%1,5151,4901,4631,4381,4201,4001,3771,3591,3391,3211,2951,2741,2471,2301,2141,1901,1711,1561,1381,1281,109
Shares Outstanding0.1%83.0083.0083.0083.0084.0084.0085.0085.0085.0086.0085.0085.0085.0085.0085.0086.0086.0086.0086.0087.0087.00
Minority Interest--------1.001.001.001.001.000.000.000.000.000.000.000.000.000.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations22.0%747612543580578746756765770745648585524453459439418400400386386
  Share Based Compensation5.7%56.0053.0050.0046.0043.0040.0038.0036.0034.0033.0031.0040.0041.0040.0039.0029.0026.0026.0025.0025.0024.00
Cashflow From Investing14.3%-165-193-195-190-190-310-292-264-234-84.29-109-189-207-216-205-149-166-159139154167
Cashflow From Financing-11.7%-562-503-370-420-492-581-697-531-413-394-248-323-318-266-286-329-314-275-597-558-541
  Buy Backs-55.4%247553820990999881747502321132183324409430302267254340369318302

IDXX Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 943,630$ 860,546$ 1,843,825$ 1,697,095
Cost of Revenue:    
Cost of revenue370,780346,514728,004684,310
Gross profit572,850514,0321,115,8211,012,785
Expenses:    
Sales and marketing140,532130,257288,336262,549
General and administrative89,66981,488159,770159,437
Research and development46,505123,22191,172163,389
Income from operations296,144179,066576,543427,410
Interest expense(10,542)(8,317)(23,669)(15,313)
Interest income327334743477
Income before provision for income taxes285,929171,083553,617412,574
Provision for income taxes61,69339,104115,32786,630
Net income attributable to IDEXX Laboratories, Inc. stockholders$ 224,236$ 131,979$ 438,290$ 325,944
Earnings per Share:    
Basic (in USD per share)$ 2.70$ 1.57$ 5.28$ 3.87
Diluted (in USD per share)$ 2.67$ 1.56$ 5.22$ 3.82
Weighted Average Shares Outstanding:    
Basic (in shares)83,08683,92283,03984,164
Diluted (in shares)83,98384,85883,98085,222
Product revenue    
Revenue:    
Total revenue$ 540,680$ 492,518$ 1,046,622$ 970,895
Cost of Revenue:    
Cost of revenue179,999167,323353,609329,394
Service revenue    
Revenue:    
Total revenue402,950368,028797,203726,200
Cost of Revenue:    
Cost of revenue$ 190,781$ 179,191$ 374,395$ 354,916

IDXX Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 132,838$ 112,546
Accounts receivable, net461,858400,619
Inventories395,141367,823
Other current assets189,188220,489
Total current assets1,179,0251,101,477
Long-Term Assets:  
Property and equipment, net683,270649,474
Operating lease right-of-use assets114,148118,618
Goodwill364,206361,795
Intangible assets, net90,93297,672
Other long-term assets439,225417,729
Total long-term assets1,691,7811,645,288
TOTAL ASSETS2,870,8062,746,765
Current Liabilities:  
Accounts payable107,664110,221
Accrued liabilities399,425433,662
Credit facility264,000579,000
Current portion of long-term debt74,99174,982
Current portion of deferred revenue37,77937,938
Total current liabilities883,8591,235,803
Long-Term Liabilities:  
Deferred income tax liabilities5,5688,150
Long-term debt, net of current portion696,844694,387
Long-term deferred revenue, net of current portion29,05430,862
Long-term operating lease liabilities97,337101,239
Other long-term liabilities64,28367,587
Total long-term liabilities893,086902,225
Total liabilities1,776,9452,138,028
Commitments and Contingencies (Note 16)
Stockholders’ Equity:  
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,378 shares in 2023 and 107,193 shares in 2022; Outstanding: 83,060 shares in 2023 and 82,894 shares in 202210,73810,719
Additional paid-in capital1,515,1971,463,215
Deferred stock units: Outstanding: 59 units in 2023 and 58 units in 20225,5155,182
Retained earnings4,037,8193,599,529
Accumulated other comprehensive loss(73,665)(77,796)
Treasury stock, at cost: 24,318 shares in 2023 and 24,299 shares in 2022(4,401,743)(4,392,112)
Total stockholders’ equity1,093,861608,737
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 2,870,806$ 2,746,765
Jonathan J. Mazelsky
10400
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.